Oireachtas Health Committee seek age restrictions on e-cigarettes and ban on flavourings

Regulations
Jul.19.2022
The committee asked the Minister for Health to look at other countries where ages for vaping and smoking are 21.

A BAN ON flavoured e-cigarettes, e-cigarette ads on social media and bright packaging are just some of the restrictions recommended in a report on pre-legislative scrutiny on a  public health bill published on the weekend.

Oireachtas Health Committee seek age restrictions on e-cigarettes and ban on flavourings

 

The Oireachtas joint committee on health compiled suggestions for the Public Health (Tobacco and Nicotine Inhaling Products) Bill 2019 after meeting with health specialists and representatives of the vaping industry.

 

A key recommendation was that the bill should regulate the flavouring of e-cigarettes and that all flavours except for tobacco, should be strictly prohibited so as not to entice minors.

 

Speaking to the committee, the Irish Heart Foundation called e-cigarette flavours marketing tools “that are almost exclusively directed at young people because if young people are not addicted, there is no business model.”

 

The committee has stated that the Minister for Health should review international studies to consider increasing the age for buying tobacco and nicotine-inhaling products  to 21.

 

Also giving evidence to the committee, the Royal College of Physicians in Ireland (RCPI) stated that teenagers are more likely to use flavoured nicotine products than other age groups.

 

However, the RCPI also told the committee that a recent study examining the effects of a similar ban in Finland did not report a significant change in e-cigarette use post introduction.

 

Many of the proposals made by the committee indicate a desire to treat e-cigarettes more like traditional cigarettes, such as a move to introduce plain packaging rather than what the Irish Cancer Society has called “cartoon-type packaging”.

 

According to a 2019 European School Survey Project on Alcohol and Other Drugs (ESPAD) vaping among young people is now more common than smoking and more young people aged 12-17 years have tried vaping (22%) compared to adults (14%).

 

The survey also found that in 15 and 16 year olds, almost four in 10 students (39%) had tried e-cigarettes and almost one in 5 (18%) were current users.

 

However, the sale of e-cigarettes to under-18s is still not against the law despite the fact that public health officials as well as representatives of the vaping industry have been advocating for it for years.

 

In response to the report’s publication Vape Business Ireland stated that the complexity of the suggestions would only delay the bill and the under-18s ban.

 

It also claimed that the committee referred to “outdated evidence, as well as research which falls short of international standards”.

 

Another measure in the report would ban the sale of e-cigarettes from temporary units such as kiosks, stalls or marquees at festivals and introduce a license for approved sellers.

 

The report also urges that the bill  contain measures to ban all forms of e-cigarette advertising on billboards, online on all social media platforms, and influencer marketing methods.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

U.S. Expands Illicit Vape Enforcement as ATF Brings PACT Act Powers Into Trade Fraud Task Force
U.S. Expands Illicit Vape Enforcement as ATF Brings PACT Act Powers Into Trade Fraud Task Force
The U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives said on September 23 that it has joined the interagency Trade Fraud Task Force to strengthen enforcement against illegal, misdeclared and smuggled vape and tobacco products. ATF will bring its authority under the Prevent All Cigarette Trafficking Act into the task force, including registration, reporting, shipping and record-inspection requirements covering interstate sales of electronic nicotine delivery systems. ATF said the move will strengthen its ability to trace illicit products from U.S. points of entry through domestic trafficking and distribution networks.
News
Sep.28 by 2Firsts Perspectives
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's liquid-vape market is showing changes across raw-material imports, product types and sales channels after synthetic nicotine came under the Tobacco Business Act on April 24. Customs data show nicotine-analogue imports totaled 12,126 kilograms from April through August, while synthetic-nicotine imports over the same five months totaled 231,663 kilograms, just 39.3% of the amount imported in March alone. Physical liquid-vape stores tracked in Seoul and Gyeonggi Province fell 9.9%, unmanned outlets edged higher and online sales listings increased from 27,774 to 42,437. Government testing of 105 liquid inhalation products promoted as nicotine-free separately found nicotine in 13 and 6-methylnicotine in 12.
Sep.22
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
Philip Morris International (PMI) showcased IQOS heated tobacco systems and nicotine pouch products at Technovation 2026 in Buenos Aires on October 7–8, presenting research on consumer attitudes, regulatory developments and illicit cigarette trade across Latin America. PMI Chief Global Growth Officer Stefano Volpetti said smoke-free products accounted for more than 7% of the Mexico City market. Argentina repealed its heated tobacco ban in May 2026 and introduced registration requirements for tobacco and nicotine products, while local media reported nicotine pouch sales in Mendoza. A PMI-commissioned survey found that only 8% of respondents across four Latin American countries were familiar with nicotine pouches. A separate KPMG study estimated illicit cigarette consumption at 77 billion sticks across 11 markets in Latin America and Canada in 2025.
PMI
Oct.13
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22